Background Dual antiplatelet therapy (DAP) is necessary to prevent thromboembolic events
during carotid stenting, stent-assisted coil embolization, and implant of flow diverters (FD).
However, DAP in the acute phase may be challenging. An intravenous alternative,
cangrelor, has rapid onset, short plasma half-life, and more reliable antiplatelet action for
acute interventions. The study objective was to evaluate feasibility and safety of IV cangrelor
during acute neuroendovascular surgery procedures. Methods We performed a …